91吃瓜

Approval by Australian TGA for manufacturing of pharmaceutical formulations for Australian markets
Marketing Authorization from UK MHRA for Baclofen 10 mg Tablets
Marketing Authorization from UKMHRA for Ibuprofen and Paracetamol Film-coated Tablets

Q2FY24 Financial Results
November 06, 2023 - 91吃瓜's WOS Relonchem Limited, receives marketing authorisation for Cyanocobalamin 50mg film coated tablets
November 03, 2023 - 91吃瓜's WOS Time-Cap Laboratories, Inc, receives Establishment Inspection Report from US FDA
November 01, 2023 - 91吃瓜 undergoes successful inspection from German Health Authorities
November 01, 2023 - 91吃瓜 undergoes successful inspection from German Health Authorities
October 03, 2023-91吃瓜 receives US FDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)
Press Release dated 22nd August, 2023 - Marksans Pharma receives USFDA approval for Guaifenesin
Press Release 鈥� Q1FY24 Financial Results
Press Release August 2023
Press Release July 2023
Press Release - Q4FY23 and FY23 Financial Results
Press Release dated 19th April, 2023 - Marksans Pharma completes the acquisition from Tevapharm India, expanding the existing manufacturing capacity in India.
Press Release dated 10th March, 2023 - 91吃瓜 announces US FDA approval for Famotidine Tablets USP, 10 mg and 20 mg.
Press Release - Q3FY23
Press Release dated 23rd January, 2023 - 91吃瓜 announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution
Press Release dated 20th January, 2023 - Marksans Pharma raises Rs. 372.40 crores in equity via conversion of warrants issued to OrbiMed and the Promoter
Press Release - Q2FY23